Gandhinagar (Gujarat), June 25 (ANI): Gujarat Biotechnology University (GBU), in collaboration with Celliimune Biotech, is spearheading a transformative initiative to develop a cost-effective, indigenous version of CAR-T cell therapy—an advanced cancer treatment currently priced at ₹3–4 crore per dose abroad. With support from the Gujarat government, GBU will focus on cutting-edge research, while Celliimune leads production and clinical trials. CAR-T therapy involves genetically modifying a patient’s T-cells to identify and destroy cancer cells, especially in leukemia and lymphoma cases, showing remarkable success even in terminal patients.